Latest Pharma Insights
J&J Pledges $1bn To Expand Florida’s ACUVUE Contact Lens Operations
To meet rising demand for ACUVUE lenses, J&J is investing $1bn in its Jacksonville, Florida, Vision operations, with plans including a new distribution facility. The investment is part of its $55bn US manufacturing commitment through 2029.
Medtech Insight - June 15, 2026
To meet rising demand for ACUVUE lenses, J&J is investing $1bn in its Jacksonville, Florida, Vision operations, with plans including a new distribution facility. The investment is part of its $55bn US manufacturing commitment through 2029.
Medtech Insight - June 15, 2026
Stelo Pediatric 510(k) Clearance Marks First OTC CGM For Children, Backed By Real-World Data
The FDA has cleared Dexcom's Stelo continuous glucose monitor for OTC use by children ages 2 and up who do not use insulin, making it the first nonprescription CGM cleared for pediatric use. The authorization was supported in part by real-world evidence.
Medtech Insight - June 15, 2026
The FDA has cleared Dexcom's Stelo continuous glucose monitor for OTC use by children ages 2 and up who do not use insulin, making it the first nonprescription CGM cleared for pediatric use. The authorization was supported in part by real-world evidence.
Medtech Insight - June 15, 2026
Elicio Confident In Phase III Plan Despite Phase II Miss In Pancreatic Cancer
Vaccine candidate ELI-002 failed to demonstrate disease-free survival in adjuvant mKRAS-driven PDAC, but Elicio thinks limiting Phase III to patients with no residual disease might show benefit.
Scrip - June 15, 2026
Vaccine candidate ELI-002 failed to demonstrate disease-free survival in adjuvant mKRAS-driven PDAC, but Elicio thinks limiting Phase III to patients with no residual disease might show benefit.
Scrip - June 15, 2026
Not Getting WISeR: Lawmakers Seek To Block Funding For AI Medicare Authorization Model
In a unanimous vote across party lines, the House Appropriations Committee agreed to cut off funds going to WISeR, a model that uses AI to conduct prior authorizations of Medicare claims. Senate Democrats are also trying to kill the model, which has already been implemented in six states.
Medtech Insight - June 15, 2026
In a unanimous vote across party lines, the House Appropriations Committee agreed to cut off funds going to WISeR, a model that uses AI to conduct prior authorizations of Medicare claims. Senate Democrats are also trying to kill the model, which has already been implemented in six states.
Medtech Insight - June 15, 2026
EHA: J&J’s Talvey Set To Move Into Earlier Treatment Lines
The drugmaker presented positive data from the Phase III MonumenTAL-3 trial in second-line and later multiple myeloma at EHA, but an investigator said most patients will likely receive BCMA-targeting drugs before Talvey.
Scrip - June 15, 2026
The drugmaker presented positive data from the Phase III MonumenTAL-3 trial in second-line and later multiple myeloma at EHA, but an investigator said most patients will likely receive BCMA-targeting drugs before Talvey.
Scrip - June 15, 2026
Penumbra Calls Rival Stroke Devices Analog. FDA-Cleared THUNDERBOLT Is Its Answer
Penumbra has received FDA clearance for THUNDERBOLT, a computer-assisted stroke thrombectomy system it says moves beyond the mechanical approach that has defined the market for years — and its president is not subtle about who she thinks has been standing still.
Medtech Insight - June 15, 2026
Penumbra has received FDA clearance for THUNDERBOLT, a computer-assisted stroke thrombectomy system it says moves beyond the mechanical approach that has defined the market for years — and its president is not subtle about who she thinks has been standing still.
Medtech Insight - June 15, 2026
Fragrance Foundation USA 2026 Award Winners
The Fragrance Foundation held its US fragrance annual awards ceremony in Lincoln Center in New York June 11.
HBW Insight - June 15, 2026
The Fragrance Foundation held its US fragrance annual awards ceremony in Lincoln Center in New York June 11.
HBW Insight - June 15, 2026
Deals Shaping The Industry, May 2026
An interactive look at pharma, medtech and diagnostics deals made during May 2026. Data courtesy of Biomedtracker.
In Vivo - June 15, 2026
An interactive look at pharma, medtech and diagnostics deals made during May 2026. Data courtesy of Biomedtracker.
In Vivo - June 15, 2026
Iran Deal In Place, But API Prices Stay Elevated And Pharma Supply Chains Face A Slow Recovery
A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.
Scrip - June 15, 2026
A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.
Scrip - June 15, 2026
Easy Access To GLP-1s Is Causing Big Problems For Obesity Studies
Participants are quitting placebo arms of obesity studies or seeking out commercially available GLP-1 drugs while staying on the trial, causing problems for developers hoping to catch up with the frontrunners.
Scrip - June 15, 2026
Participants are quitting placebo arms of obesity studies or seeking out commercially available GLP-1 drugs while staying on the trial, causing problems for developers hoping to catch up with the frontrunners.
Scrip - June 15, 2026
Aurobindo Looks To Bolster French Footprint With Facility Purchase
Aurobindo has enhanced its operations in France by acquiring a former Bristol Myers Squibb manufacturing facility through its local Arrow subsidiary.
Generics Bulletin - June 15, 2026
Aurobindo has enhanced its operations in France by acquiring a former Bristol Myers Squibb manufacturing facility through its local Arrow subsidiary.
Generics Bulletin - June 15, 2026
Formycon Started 2026 On A Strong Financial Note – Can It Be Maintained?
With its full-year guidance now confirmed, Formycon's numbers are moving in the right direction after a difficult 2025.
Generics Bulletin - June 15, 2026
With its full-year guidance now confirmed, Formycon's numbers are moving in the right direction after a difficult 2025.
Generics Bulletin - June 15, 2026
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Scrip - June 15, 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Scrip - June 15, 2026
Brazil Aligns With Global Consensus On Biosimilar Switching
Anvisa says biosimilar switching can be done safely under approved conditions, aligning Brazil with international regulators while stressing monitoring, traceability and safeguards against unplanned changes.
Generics Bulletin - June 15, 2026
Anvisa says biosimilar switching can be done safely under approved conditions, aligning Brazil with international regulators while stressing monitoring, traceability and safeguards against unplanned changes.
Generics Bulletin - June 15, 2026
Generics Pricing Pact Gives Canada Two More Years
Canada’s pCPA and CGPA have extended their national generic-drug pricing framework to 2028, preserving cost-control measures, price predictability and supply certainty for medicines reimbursed by public drug plans.
Generics Bulletin - June 15, 2026
Canada’s pCPA and CGPA have extended their national generic-drug pricing framework to 2028, preserving cost-control measures, price predictability and supply certainty for medicines reimbursed by public drug plans.
Generics Bulletin - June 15, 2026
EHA 2026: Legend Impresses With Early In Vivo CAR-T Results In Lymphoma
Already a leader in traditional CAR-Ts, Legend is moving fast with its in vivo platform.
Scrip - June 15, 2026
Already a leader in traditional CAR-Ts, Legend is moving fast with its in vivo platform.
Scrip - June 15, 2026
The Socio-Economic Case For Prevention, With Deloitte’s Elizabeth Hampson
In this episode of the Over the Counter Podcast, HBW Insight talks to Deloitte's Elizabeth Hampson about the growing role of self-care in prevention, where OTC, VMS and digital health fit, and why health literacy is the biggest opportunity for consumer health companies.
HBW Insight - June 15, 2026
In this episode of the Over the Counter Podcast, HBW Insight talks to Deloitte's Elizabeth Hampson about the growing role of self-care in prevention, where OTC, VMS and digital health fit, and why health literacy is the biggest opportunity for consumer health companies.
HBW Insight - June 15, 2026
‘The Rules Of The Market Are Changing’ – How Generation Z Will Reshape Consumer Health
Gen Z is upending the consumer health market, demanding transparency and proven efficacy from both OTCs and supplements. Porsche Consulting’s Dr. Roman Hipp warns that companies failing to adapt risk missing out on the growth opportunity presented by this increasingly influential demographic.
HBW Insight - June 15, 2026
Gen Z is upending the consumer health market, demanding transparency and proven efficacy from both OTCs and supplements. Porsche Consulting’s Dr. Roman Hipp warns that companies failing to adapt risk missing out on the growth opportunity presented by this increasingly influential demographic.
HBW Insight - June 15, 2026
Medtech’s AI Literacy Problem Is Also A Manufacturer Liability Problem
Watered-down and imprecise AI training obligations for users of medtech in the EU come at a time when doctors are most in need of new skills.
In Vivo - June 15, 2026
Watered-down and imprecise AI training obligations for users of medtech in the EU come at a time when doctors are most in need of new skills.
In Vivo - June 15, 2026
ADA 2026: Lilly And Novo Hold The Line, But The Challengers Are Coming
Lilly's retatrutide matched bariatric surgery weight loss results at ADA 2026, while a diverse challenger field in injectables, oral therapies and novel mechanisms is closing fast.
In Vivo - June 15, 2026
Lilly's retatrutide matched bariatric surgery weight loss results at ADA 2026, while a diverse challenger field in injectables, oral therapies and novel mechanisms is closing fast.
In Vivo - June 15, 2026
The New AI Trust Moat: How Medical Societies Are Becoming Gatekeepers Of Clinical Intelligence
From ASCO to the AMA, physician organizations are asserting ownership over how their guidelines appear in AI systems—turning clinical knowledge into a controlled, licensable asset and redrawing the competitive map for health-tech companies.
Medtech Insight - June 15, 2026
From ASCO to the AMA, physician organizations are asserting ownership over how their guidelines appear in AI systems—turning clinical knowledge into a controlled, licensable asset and redrawing the competitive map for health-tech companies.
Medtech Insight - June 15, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Lilly explores Zepbound in autoimmune disorders; AstraZeneca pursues interconnected strategy in CVRM; AstraZeneca moving oral GLP-1 into Phase III; Boehringer pursues quality weight loss with survodutide; and GSK scales oncology ambitions with Nuvalent buy.
Scrip - June 15, 2026
In this week's episode: Lilly explores Zepbound in autoimmune disorders; AstraZeneca pursues interconnected strategy in CVRM; AstraZeneca moving oral GLP-1 into Phase III; Boehringer pursues quality weight loss with survodutide; and GSK scales oncology ambitions with Nuvalent buy.
Scrip - June 15, 2026
Latest FTC Target Of False Supplement Ad Claims Complaint Alleged To Be Repeat Offender
“Amare’s misconduct is particularly egregious” because its “leadership has included two key players already subject to prior court-ordered permanent injunctions prohibiting them from making false, misleading, or unsubstantiated claims,” according to FTC complaint.
HBW Insight - June 15, 2026
“Amare’s misconduct is particularly egregious” because its “leadership has included two key players already subject to prior court-ordered permanent injunctions prohibiting them from making false, misleading, or unsubstantiated claims,” according to FTC complaint.
HBW Insight - June 15, 2026
Elicio Confident In Phase III Plan Despite Phase II Miss In Pancreatic Cancer
Vaccine candidate ELI-002 failed to demonstrate disease-free survival in adjuvant mKRAS-driven PDAC, but Elicio thinks limiting Phase III to patients with no residual disease might show benefit.
Scrip - June 15, 2026
Vaccine candidate ELI-002 failed to demonstrate disease-free survival in adjuvant mKRAS-driven PDAC, but Elicio thinks limiting Phase III to patients with no residual disease might show benefit.
Scrip - June 15, 2026
EHA: J&J’s Talvey Set To Move Into Earlier Treatment Lines
The drugmaker presented positive data from the Phase III MonumenTAL-3 trial in second-line and later multiple myeloma at EHA, but an investigator said most patients will likely receive BCMA-targeting drugs before Talvey.
Scrip - June 15, 2026
The drugmaker presented positive data from the Phase III MonumenTAL-3 trial in second-line and later multiple myeloma at EHA, but an investigator said most patients will likely receive BCMA-targeting drugs before Talvey.
Scrip - June 15, 2026
Iran Deal In Place, But API Prices Stay Elevated And Pharma Supply Chains Face A Slow Recovery
A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.
Scrip - June 15, 2026
A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.
Scrip - June 15, 2026
Easy Access To GLP-1s Is Causing Big Problems For Obesity Studies
Participants are quitting placebo arms of obesity studies or seeking out commercially available GLP-1 drugs while staying on the trial, causing problems for developers hoping to catch up with the frontrunners.
Scrip - June 15, 2026
Participants are quitting placebo arms of obesity studies or seeking out commercially available GLP-1 drugs while staying on the trial, causing problems for developers hoping to catch up with the frontrunners.
Scrip - June 15, 2026
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Scrip - June 15, 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Scrip - June 15, 2026
EHA 2026: Legend Impresses With Early In Vivo CAR-T Results In Lymphoma
Already a leader in traditional CAR-Ts, Legend is moving fast with its in vivo platform.
Scrip - June 15, 2026
Already a leader in traditional CAR-Ts, Legend is moving fast with its in vivo platform.
Scrip - June 15, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Lilly explores Zepbound in autoimmune disorders; AstraZeneca pursues interconnected strategy in CVRM; AstraZeneca moving oral GLP-1 into Phase III; Boehringer pursues quality weight loss with survodutide; and GSK scales oncology ambitions with Nuvalent buy.
Scrip - June 15, 2026
In this week's episode: Lilly explores Zepbound in autoimmune disorders; AstraZeneca pursues interconnected strategy in CVRM; AstraZeneca moving oral GLP-1 into Phase III; Boehringer pursues quality weight loss with survodutide; and GSK scales oncology ambitions with Nuvalent buy.
Scrip - June 15, 2026
J&J Pledges $1bn To Expand Florida’s ACUVUE Contact Lens Operations
To meet rising demand for ACUVUE lenses, J&J is investing $1bn in its Jacksonville, Florida, Vision operations, with plans including a new distribution facility. The investment is part of its $55bn US manufacturing commitment through 2029.
Medtech Insight - June 15, 2026
To meet rising demand for ACUVUE lenses, J&J is investing $1bn in its Jacksonville, Florida, Vision operations, with plans including a new distribution facility. The investment is part of its $55bn US manufacturing commitment through 2029.
Medtech Insight - June 15, 2026
Stelo Pediatric 510(k) Clearance Marks First OTC CGM For Children, Backed By Real-World Data
The FDA has cleared Dexcom's Stelo continuous glucose monitor for OTC use by children ages 2 and up who do not use insulin, making it the first nonprescription CGM cleared for pediatric use. The authorization was supported in part by real-world evidence.
Medtech Insight - June 15, 2026
The FDA has cleared Dexcom's Stelo continuous glucose monitor for OTC use by children ages 2 and up who do not use insulin, making it the first nonprescription CGM cleared for pediatric use. The authorization was supported in part by real-world evidence.
Medtech Insight - June 15, 2026
Not Getting WISeR: Lawmakers Seek To Block Funding For AI Medicare Authorization Model
In a unanimous vote across party lines, the House Appropriations Committee agreed to cut off funds going to WISeR, a model that uses AI to conduct prior authorizations of Medicare claims. Senate Democrats are also trying to kill the model, which has already been implemented in six states.
Medtech Insight - June 15, 2026
In a unanimous vote across party lines, the House Appropriations Committee agreed to cut off funds going to WISeR, a model that uses AI to conduct prior authorizations of Medicare claims. Senate Democrats are also trying to kill the model, which has already been implemented in six states.
Medtech Insight - June 15, 2026
Penumbra Calls Rival Stroke Devices Analog. FDA-Cleared THUNDERBOLT Is Its Answer
Penumbra has received FDA clearance for THUNDERBOLT, a computer-assisted stroke thrombectomy system it says moves beyond the mechanical approach that has defined the market for years — and its president is not subtle about who she thinks has been standing still.
Medtech Insight - June 15, 2026
Penumbra has received FDA clearance for THUNDERBOLT, a computer-assisted stroke thrombectomy system it says moves beyond the mechanical approach that has defined the market for years — and its president is not subtle about who she thinks has been standing still.
Medtech Insight - June 15, 2026
The New AI Trust Moat: How Medical Societies Are Becoming Gatekeepers Of Clinical Intelligence
From ASCO to the AMA, physician organizations are asserting ownership over how their guidelines appear in AI systems—turning clinical knowledge into a controlled, licensable asset and redrawing the competitive map for health-tech companies.
Medtech Insight - June 15, 2026
From ASCO to the AMA, physician organizations are asserting ownership over how their guidelines appear in AI systems—turning clinical knowledge into a controlled, licensable asset and redrawing the competitive map for health-tech companies.
Medtech Insight - June 15, 2026
Fragrance Foundation USA 2026 Award Winners
The Fragrance Foundation held its US fragrance annual awards ceremony in Lincoln Center in New York June 11.
HBW Insight - June 15, 2026
The Fragrance Foundation held its US fragrance annual awards ceremony in Lincoln Center in New York June 11.
HBW Insight - June 15, 2026
The Socio-Economic Case For Prevention, With Deloitte’s Elizabeth Hampson
In this episode of the Over the Counter Podcast, HBW Insight talks to Deloitte's Elizabeth Hampson about the growing role of self-care in prevention, where OTC, VMS and digital health fit, and why health literacy is the biggest opportunity for consumer health companies.
HBW Insight - June 15, 2026
In this episode of the Over the Counter Podcast, HBW Insight talks to Deloitte's Elizabeth Hampson about the growing role of self-care in prevention, where OTC, VMS and digital health fit, and why health literacy is the biggest opportunity for consumer health companies.
HBW Insight - June 15, 2026
‘The Rules Of The Market Are Changing’ – How Generation Z Will Reshape Consumer Health
Gen Z is upending the consumer health market, demanding transparency and proven efficacy from both OTCs and supplements. Porsche Consulting’s Dr. Roman Hipp warns that companies failing to adapt risk missing out on the growth opportunity presented by this increasingly influential demographic.
HBW Insight - June 15, 2026
Gen Z is upending the consumer health market, demanding transparency and proven efficacy from both OTCs and supplements. Porsche Consulting’s Dr. Roman Hipp warns that companies failing to adapt risk missing out on the growth opportunity presented by this increasingly influential demographic.
HBW Insight - June 15, 2026
Latest FTC Target Of False Supplement Ad Claims Complaint Alleged To Be Repeat Offender
“Amare’s misconduct is particularly egregious” because its “leadership has included two key players already subject to prior court-ordered permanent injunctions prohibiting them from making false, misleading, or unsubstantiated claims,” according to FTC complaint.
HBW Insight - June 15, 2026
“Amare’s misconduct is particularly egregious” because its “leadership has included two key players already subject to prior court-ordered permanent injunctions prohibiting them from making false, misleading, or unsubstantiated claims,” according to FTC complaint.
HBW Insight - June 15, 2026
Aurobindo Looks To Bolster French Footprint With Facility Purchase
Aurobindo has enhanced its operations in France by acquiring a former Bristol Myers Squibb manufacturing facility through its local Arrow subsidiary.
Generics Bulletin - June 15, 2026
Aurobindo has enhanced its operations in France by acquiring a former Bristol Myers Squibb manufacturing facility through its local Arrow subsidiary.
Generics Bulletin - June 15, 2026
Formycon Started 2026 On A Strong Financial Note – Can It Be Maintained?
With its full-year guidance now confirmed, Formycon's numbers are moving in the right direction after a difficult 2025.
Generics Bulletin - June 15, 2026
With its full-year guidance now confirmed, Formycon's numbers are moving in the right direction after a difficult 2025.
Generics Bulletin - June 15, 2026
Brazil Aligns With Global Consensus On Biosimilar Switching
Anvisa says biosimilar switching can be done safely under approved conditions, aligning Brazil with international regulators while stressing monitoring, traceability and safeguards against unplanned changes.
Generics Bulletin - June 15, 2026
Anvisa says biosimilar switching can be done safely under approved conditions, aligning Brazil with international regulators while stressing monitoring, traceability and safeguards against unplanned changes.
Generics Bulletin - June 15, 2026
Generics Pricing Pact Gives Canada Two More Years
Canada’s pCPA and CGPA have extended their national generic-drug pricing framework to 2028, preserving cost-control measures, price predictability and supply certainty for medicines reimbursed by public drug plans.
Generics Bulletin - June 15, 2026
Canada’s pCPA and CGPA have extended their national generic-drug pricing framework to 2028, preserving cost-control measures, price predictability and supply certainty for medicines reimbursed by public drug plans.
Generics Bulletin - June 15, 2026
Deals Shaping The Industry, May 2026
An interactive look at pharma, medtech and diagnostics deals made during May 2026. Data courtesy of Biomedtracker.
In Vivo - June 15, 2026
An interactive look at pharma, medtech and diagnostics deals made during May 2026. Data courtesy of Biomedtracker.
In Vivo - June 15, 2026
Medtech’s AI Literacy Problem Is Also A Manufacturer Liability Problem
Watered-down and imprecise AI training obligations for users of medtech in the EU come at a time when doctors are most in need of new skills.
In Vivo - June 15, 2026
Watered-down and imprecise AI training obligations for users of medtech in the EU come at a time when doctors are most in need of new skills.
In Vivo - June 15, 2026
ADA 2026: Lilly And Novo Hold The Line, But The Challengers Are Coming
Lilly's retatrutide matched bariatric surgery weight loss results at ADA 2026, while a diverse challenger field in injectables, oral therapies and novel mechanisms is closing fast.
In Vivo - June 15, 2026
Lilly's retatrutide matched bariatric surgery weight loss results at ADA 2026, while a diverse challenger field in injectables, oral therapies and novel mechanisms is closing fast.
In Vivo - June 15, 2026